Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 13,784 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: IW-1973, Placebo Oral Tablet; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 45 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 57
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: Medulloblastoma
Interventions: Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate; Drug · Radiation · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Tropifexor (LJN452), Cenicriviroc (CVC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 62
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 43 more

Conditions: Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Months to 20 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 46
States / cities: Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more

Conditions: Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions: AZ-3102, Placebo; Drug
Lead sponsor: Azafaros B.V.; Industry
Eligibility: 4 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more

Conditions: Atrial Fibrillation
Interventions: Surgical Ablation using the AtriCure Bipolar System; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 5
States / cities: Tampa, Florida • Cincinnati, Ohio • Oklahoma City, Oklahoma + 2 more

Conditions: Pulmonary Arterial Hypertension
Interventions: i.v. selexipag, oral selexipag (Uptravi); Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Conditions: Arthritis, Rheumatoid
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Murrieta, California • Longmont, Colorado • Lewes, Delaware + 27 more

Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PTM-101; Drug
Lead sponsor: PanTher Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more

Conditions: Kidney Disease, Nephropathy, Type 2 Diabetes
Interventions: losartan, lisinopril; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 92
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Acute Ischemic Stroke
Interventions: TAK-755, Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more

Conditions: Locally Advanced or Metastatic Unresectable Urothelial Cancer
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 17 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK4527363, Placebo matching GSK4527363, Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more

Conditions: Venous Vascular Closure
Interventions: MYNX CONTROL™ Venous Vascular Closure Device 6F-12F; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Phoenix, Arizona • Lakewood, Colorado • Miami, Florida + 10 more

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 50
States / cities: Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more

Conditions: Malocclusion, Angle Class II
Interventions: Aligners, Clear braces; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 17 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Pain, Postoperative, Hernia, Inguinal
Interventions: Pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 17 Years to 75 Years · Male only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, California • Laguna Hills, California + 16 more

Conditions: Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions: Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 29
States / cities: Culver City, California • Los Angeles, California • Sacramento, California + 21 more

Conditions: Painful Diabetic Peripheral Neuropathy
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Prostate Cancer
Interventions: calcitriol, docetaxel; Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 52
States / cities: Montgomery, Alabama • Scottsdale, Arizona • Tucson, Arizona + 44 more

Search by objective public record fields.

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Sole-Therapy Treatment of Atrial Fibrillation

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

VA NEPHRON-D: Diabetes iN Nephropathy Study

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

A Study of TAK-755 in Adults With Acute Ischemic Stroke

Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

RCT Comparing Invisalign and Traditional Orthodontic Treatment

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere